Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Stephen Maxwell MontgomeryFern Amy WoodhouseUmakanth VudumulaK GudalaMartin Edward DuddyM KroesPublished in: Journal of medical economics (2022)
Recognition of active SPMS and treatment of this phenotype with siponimod offers a cost-effective and clinically beneficial treatment approach compared with the continuation of oral or infused RRMS DMTs.